Navigation Links
FDA Approves First Anti-Psychotic for Kids
Date:8/22/2007

Risperdal had been used off-label to treat children with schizophrenia, bipolar disorder

WEDNESDAY, Aug. 22 (HealthDay News) -- The powerful anti-psychotic drug Risperdal was approved by the U.S. and Food Administration on Wednesday for use in children and adolescents who have schizophrenia or bipolar disorder.

Until this point, the agency hadn't approved any drug for the treatment of adolescent schizophrenia. For bipolar disorder, only lithium is approved for use in adolescents aged 12 and older.

"The FDA has approved Risperdal for treating schizophrenia in adolescents 13 to 17 and for the short-term [three-week] treatment of bipolar I disorder in children and adolescents 10 to 17," Dr. Thomas Laughren, director of the Division of Psychiatry Products at the agency's Center for Drug Evaluation and Research, said during a midday teleconference.

One expert thinks the move is warranted.

"This is a drug that has real value," said Dr. Charles Goodstein, a clinical professor of psychiatry at New York University Medical School. "But one has to exercise a degree of caution when using what amount to be heavy-duty medications in young children and adolescents."

Goodstein noted that diagnosing children with these conditions is difficult, and that can lead to misdiagnosis and the prescribing of inappropriate medications. "One has to very careful that this medication is not overused," he said.

"Bottom line, it's a valuable medication, one that can produce momentous changes in a person's functioning, but a medication that should be used with great care, because it does have side effects, and too often diagnoses are made more readily than they should be made," Goodstein said.

The agency first approved Risperdal (risperidone) in 1993 for treating schizophrenia in adults. It was approved subsequently for the short-term treatment of acute manic or mixed episodes of bipolar I disorder in adults and the treatment of irritability associated autism in children and adolescents aged 5 to 16, Laughren noted.

Risperdal brought in $2.3 billion in sales in 2005, according to the Associated Press.

Laughren said the medication belongs to a class of powerful drugs that do have side effects, but they are used to treat disabling conditions that fail to respond to other medications.

"Both of these disorders are commonly treated off-label in pediatric patients with Risperdal and other drugs that are approved for treating these conditions in adults," Laughren said.

The FDA based its approval for using the drug with schizophrenic adolescents on the results of two short-term trials. Patients taking the drug had fewer symptoms, including fewer hallucinations and less delusional thinking.

In terms of bipolar disorder, the agency relied on the outcome of a three-week trial among children and adolescents with bipolar I disorder. In this trial, patients taking Risperdal had fewer symptoms, including a reduction in elevated mood and hyperactivity, the agency noted.

Common side effects of Risperdal include drowsiness, fatigue, increased appetite, anxiety, nausea, dizziness, dry mouth, tremor and rash. "This adverse event profile is similar to what we have seen in adults who are treated with these medications," Laughren said.

However, Laughren noted Risperdal might also affect growth and development in adolescents, so the FDA has asked the drug's maker, Janssen, L.P., of Titusville, N.J., to begin a study to look a those potential problems.

Schizophrenia is a disabling psychiatric disorder with symptoms that can include hallucinations, delusions, and disorganized thinking. Bipolar disorder, also known as manic-depressive illness, causes shifts in mood, energy and ability to function.

More information

For more information on Risperdal, visit the U.S. Food and Drug Administration.



SOURCES: Aug. 22, 2007, teleconference with Thomas Laughren, M.D., director, Division of Psychiatry Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Charles Goodstein, M.D., clinical professor, psychiatry, New York University Medical School, New York City, and psychiatrist, Tenafly, N.J.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA approves new device to treat womens bleeding disorder
3. FDA Approves New HIV Drug, Viread
4. FDA Approves Birth Control Skin Patch
5. FDA approves surgical gel
6. FDA Approves New Arthritis Drug, Bextra
7. FDA Approves Elidel Cream for Eczema
8. FDA approves drug for rare liver disease
9. FDA approves first pocket-sized EKG machine
10. FDA Approves New Anti-Clotting Drug
11. FDA Approves New surgery Treatment for Farsightedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2018)... ... August 14, 2018 , ... Gastro Health, LLC (“Gastro ... for healthcare executives Simon Frisch and Chris Weinstein, who have been appointed Senior ... roles at a time of tremendous growth for the group, which has increased ...
(Date:8/14/2018)... ... August 14, 2018 , ... Eagle ... Group, a leading provider of residential and commercial recreational surfacing products across the ... industry, with products used across a wide range of markets and customers. Founded ...
(Date:8/11/2018)... OVERLAND PARK, Kan. (PRWEB) , ... August 10, ... ... Gout Gone, an industry leader in Gout Relief. , What is gout? This ... the lower extremities as a result of high levels of uric acid. Other ...
(Date:8/11/2018)... (PRWEB) , ... August 11, 2018 , ... ... of a Silver Stevie® Award in the Executive of the Year-Business category in ... world’s premier business awards program. All individuals and organizations worldwide – public and ...
(Date:8/9/2018)... ... August 09, 2018 , ... Balboa Horizons, an industry ... process that substance abuse providers must pass in order to advertise on Google. ... people to help.” , Helping people is what Balboa Horizons is all ...
Breaking Medicine News(10 mins):
(Date:8/11/2018)... SAN FRANCISCO (PRWEB) , ... August 10, 2018 , ... ... round financial advisor, following a $2 million seed funding round. Carepoynt is an emerging ... consumers at the center of a more rewarding and engaging healthcare ecosystem. , Headquartered ...
(Date:8/11/2018)... ... August 11, 2018 , ... ... of ‘Information Matrix’ on integrative medicine. The episode will go through different integrative ... society. , Integrative medicine involves using both conventional and complementary approaches to health ...
(Date:8/9/2018)... ... 2018 , ... Doctor Snehal Patel is offering the residents of South Fairfax ... September 30th, applicants who are in need of full-arch restorations, but who otherwise couldn’t ... Project Smile Program. , "Our local communities have been very good to us and ...
Breaking Medicine Technology: